The primary objective of the trial is to provide continued access to TMC278 for subjects who were randomized and treated with TMC278 in the Phase IIb C204 or Phase III trials C209 and C215 and who at the time of roll-over experience and are expected to continue experiencing clinical benefit from TMC278 treatment
Data and Resources
- An open-label trial with TMC278 25 mg qd in combination with a background regimen containing 2 nucleosidenucleotide reverse transcriptase inhibitors in HIV-1 infected subjects who participated in TMC278 clinical trialsjson
The primary objective of the trial is to provide continued access to TMC278...
|Release Date|| |
License Not Specified
|Public Access Level|| |